Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Ali Aminian
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07027969CT.gov Metabolic Surgery for Atrial Fibrillation Elimination | — | Not Yet Recruiting | — | — | — |
NCT07331389CT.gov A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin | — | Recruiting | — | — | — |
NCT07336797CT.gov Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy | — | Recruiting | — | — | — |
NCT07120828CT.gov The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity | — | Completed | — | — | — |
NCT06745063CT.gov Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity | — | Recruiting | — | — | — |
NCT05885074CT.gov Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors | — | Withdrawn | — | — | — |
NCT05972564CT.gov The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function | — | Recruiting | — | — | — |
NCT05426525CT.gov Use of Empagliflozin to Treat Prediabetes | — | Active Not Recruiting | — | — | — |
NCT04143581CT.gov SGLT2 Inhibitors in Glomerular Hyperfiltration | — | Withdrawn | — | — | — |
NCT05084235CT.gov The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT05042973CT.gov The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure | — | Completed | — | — | — |
NCT04583813CT.gov Empagliflozin and Atrial Fibrillation Treatment | — | Unknown | — | — | — |
NCT04907214CT.gov SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot | — | Completed | — | — | — |
NCT03912909CT.gov Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans | — | Unknown | — | — | — |
NCT02632747CT.gov Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Empagliflozin (this asset) | Ali Aminian | Approved | BB · 64 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Empagliflozin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | BBB · 74 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BBB · 73 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Empagliflozin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/empagliflozin-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →